Immunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugs
Authors:
- 1 February 1997
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 41 (2) , 251-258
Abstract
Congenitally immunodeficient and immunosuppressed normal mice with naturally acquired Pneumocystis carinii infection were compared as models for testing anti-P. carinii drugs. Among the immunodeficient mice, mice with severe combined immunodeficiency disease (scid), which lack B and T cells, had higher levels of P. carinii pneumonia than did microMT mice, which lack K cells. Normal mice administered dexamethasone in the drinking water had more extensive pneumocystosis than mice administered parenteral methylprednisolone or hybridoma cells making a monoclonal antibody to CD4 cells. The standard anti-P. carinii drugs trimethoprim (TMP)-sulfamethoxazole (SMX), pentamidine, and atovaquone, which work well in rats and humans, worked well in the mice. Clindamycin and primaquine were effective in the scid and microMT mice but not in the immunosuppressed normal mice. High doses of epiroprim, an analog of TMP, appeared to enhance the activities of low doses of SMX and dapsone, while high doses of TMP did not; however, further studies are needed before definitive conclusions about the actions of these drugs can be drawn. Taken together, the data obtained in this study support the growing body of literature suggesting that the mouse is a valid alternative to the rat as a model for testing anti-P. carinii drugs. Additional differences involving the activities of individual drugs in these models will probably emerge as more experience is gained.Keywords
This publication has 27 references indexed in Scilit:
- Molecular biology and epidemiology of Pneumocystis carinii infection in AIDSAIDS, 1996
- Pneumocystis carinii Infection in Transgenic B Cell-Deficient MiceThe Journal of Infectious Diseases, 1996
- Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID miceAntimicrobial Agents and Chemotherapy, 1995
- Artificial Infections of Pneumocystis carinii in the SCID Mouse and their Use in the In Vivo Evaluation of Antipneumocystis DrugsJournal of Eukaryotic Microbiology, 1994
- Lethal exacerbation of Pneumocystis carinii pneumonia in severe combined immunodeficiency mice after infection by pneumonia virus of mice.Journal of Experimental Medicine, 1993
- Both immunity and hyperresponsiveness to Pneumocystis carinii result from transfer of CD4+ but not CD8+ T cells into severe combined immunodeficiency mice.Journal of Clinical Investigation, 1992
- Inoculated mouse model of Pneumocystis carinii infectionDiagnostic Microbiology and Infectious Disease, 1992
- A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin μ chain geneNature, 1991
- A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes.Journal of Clinical Investigation, 1990
- Nude Mouse: A New Experimental Model for Pneumocystis carinii InfectionScience, 1977